Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + tandospirone
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Union Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Escitalopram + tandospirone is a combination therapy of two small molecule drugs used primarily in the treatment of vascular depression with comorbid anxiety and chronic insomnia. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT), leading to enhanced serotonergic neurotransmission. Tandospirone is an azapirone-class anxiolytic and antidepressant that acts as a potent partial agonist at the 5-HT1A receptor, with additional weak affinity for other serotonergic and adrenergic receptors. Clinical studies have shown that this combination can accelerate the onset of antidepressant and anxiolytic effects, improve cognitive function, and enhance sleep quality in patients with vascular depression compared to monotherapy. The safety profile appears reasonable based on available clinical data[1][2][4].
- Other names
- escitalopram plus tandospironeescitalopram and tandospironeescitalopram + tandospirone citrate
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on escitalopram + tandospirone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + tandospirone.